Alnylam Pharmaceuticals Announces Positive HELIOS-B Phase 3 Results for AMVUTTRA® (Vutrisiran), Showing Reduced GI Events in ATTR-CM Patients

Reuters · 09/28/2025 15:13

Please log in to view news